1 day ago
1
Shidlovski
Shares of Ocular Therapeutix (NASDAQ:OCUL) spiked on Wednesday after the company said its Phase 3 registrational trial SOL-R for its lead asset Axpaxli for the eye disorder wet age-related macular degeneration (wet AMD) will close this week.
The global study
English (US) ·